Additional Relevant Details Researchers conducted nonclinical studies designed to evaluate the efficacy of amantadine for the treatment of MS-related symptoms, including walking impairment, in in vivo models of MS and to better understand the mechanisms of action of amantadine in MS. Data demonstrated that in models of MS, chronic administration of amantadine at a dose intended to match the human plasma levels of ADS-5102 improved walking. Additionally, data from an in vitro study demonstrated that amantadine blocked neuronal potassium channel activity, which may result in enhanced electrical impulses across demyelinated regions of neurons. Data from these studies suggest that ADS-5102 may have clinical utility in the treatment of major symptoms associated with MS, including walking impairment.